rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Peptide Drug Semax Shows Promise Against Alzheimer's Disease in Mouse Model

RPEP-131622025Radchenko, A I; Kuzubova, E V; Apostol, A A; Mitkevich, V A; Andreeva, L A; Limborska, S A; Stepenko, Yu V; Shmigerova, V S; Solin, A V; Korokin, M V; Pokrovskii, M V; Myasoedov, N F; Makarov, A A
Animal StudyLow Moderate evidence
The takeaway

The neuroprotective peptide Semax and its derivative improved behavior and reduced amyloid pathology in a transgenic Alzheimer's mouse model.

Reduced amyloidosis

Semax peptide decreased amyloid plaque pathology in Alzheimer's model mice

What the researchers found

Semax and its derivative improved behavioral performance and reduced amyloidosis in transgenic Alzheimer's mice, suggesting neuroprotective potential.

Why it matters

Safe, effective Alzheimer's treatments remain elusive; natural neuroprotective peptides like Semax could offer therapeutic benefits without the significant side effects seen in antibody-based amyloid therapies.

The numbers in context

APPswe/PS1dE9/Blg transgenic mice; improved performance in open field, novel object recognition, and Barnes maze tests; reduced amyloidosis.

How the study worked

Preclinical study in transgenic APPswe/PS1dE9/Blg mice using open field, novel object recognition, and amyloid pathology assessment.

Who was studied

APPswe/PS1dE9/Blg transgenic mice (Alzheimer's model)

What this study cannot tell us

Mouse model study — results may not translate directly to human Alzheimer's; specific dosing, treatment duration, and long-term effects need further investigation.

How to read the evidence

Preclinical animal study; promising results but human clinical trials are needed to confirm efficacy and safety.

When this study was published

Published in 2025, contributing to the growing body of peptide-based neurotherapeutic research.

The bigger picture

As antibody-based amyloid treatments face safety concerns (brain swelling, microbleeds), peptide-based neuroprotective approaches like Semax represent a potentially safer alternative strategy for Alzheimer's disease.

Questions still open

  • Can Semax or its derivatives cross the blood-brain barrier efficiently enough for human therapeutic use?
  • Would Semax work synergistically with existing Alzheimer's treatments?

Common questions

What is Semax?
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone) that has neuroprotective properties. It is used clinically in some countries for cognitive enhancement and stroke recovery, and is now being studied for Alzheimer's disease.
Could peptide drugs treat Alzheimer's disease?
This study suggests peptide drugs like Semax may reduce Alzheimer's-related brain pathology and improve behavior in animal models. Unlike antibody treatments that can cause brain swelling, peptide drugs may offer a safer therapeutic approach, though human trials are still needed.

Read the original research

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.

Acta naturae, 17(4), 110-120

View on PubMed ↗Publisher’s paper ↗

Citation

Radchenko, A I; Kuzubova, E V; Apostol, A A; Mitkevich, V A; Andreeva, L A; Limborska, S A; Stepenko, Yu V; Shmigerova, V S; Solin, A V; Korokin, M V; Pokrovskii, M V; Myasoedov, N F; Makarov, A A. (2025). The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.. Acta naturae, 17(4), 110-120. https://doi.org/10.32607/actanaturae.27808